Connor Clark & Lunn Investment Management Ltd. Grows Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Connor Clark & Lunn Investment Management Ltd. raised its position in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 38.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,228,836 shares of the company’s stock after purchasing an additional 342,781 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.32% of GoodRx worth $5,714,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Quest Partners LLC purchased a new stake in shares of GoodRx in the third quarter worth approximately $160,000. Charles Schwab Investment Management Inc. increased its stake in GoodRx by 5.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 480,123 shares of the company’s stock worth $3,332,000 after purchasing an additional 26,262 shares during the period. Dynamic Technology Lab Private Ltd increased its stake in GoodRx by 260.7% in the third quarter. Dynamic Technology Lab Private Ltd now owns 44,419 shares of the company’s stock worth $308,000 after purchasing an additional 32,104 shares during the period. Rubric Capital Management LP lifted its position in shares of GoodRx by 25.2% during the third quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company’s stock worth $32,479,000 after purchasing an additional 943,226 shares during the last quarter. Finally, Centiva Capital LP boosted its stake in shares of GoodRx by 27.5% during the third quarter. Centiva Capital LP now owns 66,233 shares of the company’s stock valued at $460,000 after purchasing an additional 14,287 shares during the period. Institutional investors own 63.77% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on GDRX. Morgan Stanley decreased their price objective on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Mizuho initiated coverage on shares of GoodRx in a research note on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price target for the company. Citigroup dropped their price objective on GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a research note on Friday, January 10th. KeyCorp decreased their target price on GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Finally, Wells Fargo & Company dropped their price target on GoodRx from $9.00 to $8.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $8.18.

GoodRx Price Performance

Shares of GDRX stock opened at $4.42 on Friday. The stock’s 50-day moving average is $4.72 and its 200 day moving average is $5.53. GoodRx Holdings, Inc. has a 1-year low of $4.09 and a 1-year high of $9.26. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The company has a market cap of $1.70 billion, a P/E ratio of -147.33, a PEG ratio of 2.46 and a beta of 1.25.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.